Assessment and management of kidney disease in the HIV-1-infected patient. A practical review;Evaluación y tratamiento de la nefropatía en el paciente con infección por VIH-1. Una revisión práctica

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 28, Issue 3, 2010, Pages 185-198

  Domingo, Pere ^a   Knobel, Hernando ^b   Gutiérrez, Félix ^c   Barril, Guillermina ^d   Fulladosa, Xavier ^e  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antiretroviral drugs; HIV 1; Kidney disease; Renal failure

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CHRONIC KIDNEY FAILURE; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG HYPERSENSITIVITY; FANCONI RENOTUBULAR SYNDROME; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTENSION; HYPOPHOSPHATEMIA; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RESISTANCE; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; MALIGNANT HYPERTENSION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MICROANGIOPATHY; MORTALITY; NEPHROLITHIASIS; NEPHROTIC SYNDROME; NEPHROTOXICITY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PERITONEAL DIALYSIS; PROTEINURIA; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; SHORT SURVEY; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUBULAR DYSFUNCTION; VITAMIN BLOOD LEVEL;

AIDS-ASSOCIATED NEPHROPATHY; ALGORITHMS; HIV-1; HUMANS; KIDNEY FUNCTION TESTS; RENAL DIALYSIS;

EID: 77949912265     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.05.004     Document Type: Short Survey

References (105)

1. Sterne J.A., Hernan M.A., Ledergerber B., Tilling K., Weber R., Sendi P., et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366 (2005) 378-384
2. Smit C., Geskus R., Walker S., Sabin C., Coutinho R., Porter K., et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 20 (2006) 741-749
3. Novoa A.M., De Olalla P.G., Clos R., Orcau A., Rodríguez-Sanz M., and Cayla J.A. Increase in the non-HIV-related deaths among AIDS cases in the HAART era. Curr HIV Res 6 (2008) 77-81
4. Selik R.M., Byers Jr. R.H., and Dworkin M.S. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 29 (2002) 378-387
5. Gupta S.K., Mamlin B.W., Johnson C.S., Dollins M.D., Topf J.M., and Dube M.P. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 61 (2004) 1-6
6. Monahan M., Tanji N., and Klotman P.E. HIV-associated nephropathy: an urban epidemic. Semin Nephrol 21 (2001) 394-402
7. Szczech L.A., Hoover D.R., Feldman J.G., Cohen M.H., Gange S.J., Gooze L., et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 39 (2004) 1199-1206
8. Valeri A., and Neusy A.J. Acute and chronic renal disease in hospitalized AIDS patients. Clin Nephrol 35 (1991) 110-118
9. Rao T.K., and Friedman E.A. Outcome of severe acute renal failure in patients with acquired immunodeficiency syndrome. Am J Kidney Dis 25 (1995) 390-398
10. Franceschini N., Napravnik S., Eron Jr. J.J., Szczech L.A., and Finn W.F. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 67 (2005) 1526-1531
11. Wyatt C.M., Arons R.R., Klotman P.E., and Klotman M.E. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 20 (2006) 561-565
12. De Silva T.I., Post F.A., Griffin M.D., and Dockrell D.H. HIV-1 infection and the kidney: an evolving challenge in HIV medicine. Mayo Clin Proc 82 (2007) 1103-1116
13. Mocroft A., Kirk O., Gatell J., Reiss P., Gargalianos P., Zilmer K., et al. Chronic renal failure among HIV-1-infected patients. AIDS 21 (2007) 1119-1127
14. Wyatt C.M., Winston J.A., Malvestutto C.D., Fishbein D.A., Barash I., Cohen A.J., et al. Chronic kidney disease in HIV infection: an urban epidemic. AIDS 21 (2007) 2101-2103
15. Sorli M.L., Guelar A., Montero M., González A., Rodríguez E., and Knobel H. Chronic kidney disease prevalence and risk factors among HIV-infected patients. J Acquir Immune Defic Syndr 48 (2008) 506-508
16. Choi A.I., Rodríguez R.A., Bacchetti P., Bertenthal D., Volberding P.A., and O'Hare A.M. The impact of HIV on chronic kidney disease outcomes. Kidney Int 72 (2007) 1380-1387
17. Trullàs JC, Barril G, Cofan F, Moreno A, Cases A, Fernández-Lucas M, et al; and the Spanish HIV Infection in Dialysis Study Group. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS Res Hum Retroviruses. 2008;24:1229-35.
18. Vigneau C., Guiard-Schmid J.B., Tourret J., Flahault A., Rozenbaum W., Pialoux G., et al. The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002. Kidney Int 67 (2005) 1509-1514
19. Finelli L., Miller J.T., Tokars J.I., Alter M.J., and Arduino M.J. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 18 (2005) 52-61
20. Casanova S., Mazzucco G., Barbiano di B.G., Motta M., Boldorini R., Genderini A., et al. Pattern of glomerular involvement in human immunodeficiency virus-infected patients: an Italian study. Am J Kidney Dis 26 (1995) 446-453
21. Gutiérrez E., Morales E., Gutiérrez M.E., Manzanares M.J., Rosello G., Merida E., et al. [Glomerulopathies associated to HIV infection: a Spanish perspective]. Nefrología 27 (2007) 439-447
22. Klotman P.E. HIV-associated nephropathy. Kidney Int 56 (1999) 1161-1176
23. Dijkman H.B., Weening J.J., Smeets B., Verrijp K.C., Van Kuppevelt T.H., Assmann K.K., et al. Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells. Kidney Int 70 (2006) 338-344
24. Cohen AH, Nast CC. Renal injury associated with human immunodeficiency virus infection. En: Jennette JC, Olson JL, Schwartz MM, Silva FG, editors. Heptinstall's pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 397-422.
25. D'Agati V., and Appel G.B. HIV infection and the kidney. J Am Soc Nephrol 8 (1997) 138-152
26. Winston J.A., Bruggeman L.A., Ross M.D., Jacobson J., Ross L., D'Agati V.D., et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 344 (2001) 1979-1984
27. Atta M.G., Gallant J.E., Rahman M.H., Nagajothi N., Racusen L.C., Scheel P.J., et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 21 (2006) 2809-2813
28. Lucas G.M., Eustace J.A., Sozio S., Mentari E.K., Appiah K.A., and Moore R.D. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 18 (2004) 541-546
29. Wali R.K., Drachenberg C.I., Papadimitriou J.C., Keay S., and Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 352 (1998) 783-784
30. Wei A., Burns G.C., Williams B.A., Mohammed N.B., Visintainer P., and Sivak S.L. Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition. Kidney Int 64 (2003) 1462-1471
31. Nochy D., Glotz D., Dosquet P., Pruna A., Guettier C., Weiss L., et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 8 (1993) 11-19
32. Szczech L.A., Gupta S.K., Habash R., Guasch A., Kalayjian R., Appel R., et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 66 (2004) 1145-1152
33. Cheng J.T., Anderson Jr. H.L., Markowitz G.S., Appel G.B., Pogue V.A., and D'Agati V.D. Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection. J Am Soc Nephrol 10 (1999) 1566-1574
34. Kamar N., Rostaing L., and Alric L. Treatment of hepatitis C-virus-related glomerulonephritis. Kidney Int 69 (2006) 436-439
35. Haas M., Kaul S., and Eustace J.A. HIV-associated immune complex glomerulonephritis with "lupus-like" features: a clinicopathologic study of 14 cases. Kidney Int 67 (2005) 1381-1390
36. Kimmel P.L., Phillips T.M., Ferreira-Centeno A., Farkas-Szallasi T., Abraham A.A., and Garrett C.T. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 327 (1992) 702-706
37. Becker S., Fusco G., Fusco J., Balu R., Gangjee S., Brennan C., et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 39 (2004) S267-S275
38. Peraldi M.N., Maslo C., Akposso K., Mougenot B., Rondeau E., and Sraer J.D. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients anad sixty renal biopsies. Nephrol Dial Transplant 14 (1999) 1578-1585
39. Weiner N.J., Goodman J.W., and Kimmel P.L. The HIV-associated renal diseases: Current insight into pathogenesis and treatment. Kidney Int 63 (2003) 1618-1631
40. Choudhury D., and Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol 2 (2006) 80-91
41. González E., Gutiérrez E., Galeano C., Chevia C., De S.P., Bernis C., et al. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73 (2008) 940-946
42. Chan-Tack K.M., Truffa M.M., Struble K.A., and Birnkrant D.B. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS 21 (2007) 1215-1218
43. Izzedine H., Launay-Vacher V., Isnard-Bagnis C., and Deray G. Drug-induced Fanconi's syndrome. Am J Kidney Dis 41 (2003) 292-309
44. Izzedine H., Isnard-Bagnis C., Hulot J.S., Vittecoq D., Cheng A., Jais C.K., et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 18 (2004) 1074-1076
45. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004) 191-201
46. Coloma Conde A.G., Álvarez Albarrán M., Roca-Cusachs Coll A., Domingo Pedrol P., and Puig Campmany M. Prevalencia de hipertensión arterial y anomalías lipídicas en pacientes VIH. Med Clin (Barc) 131 (2008) 681-684
47. Gazzaruso C., Bruno R., Garzaniti A., Giordanetti S., Fratino P., Sacchi P., et al. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 21 (2003) 1377-1382
48. Crane H.M., Van Rompaey S.E., and Kitahata M.M. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 20 (2006) 1019-1026
49. Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 165 (2005) 1179-1184
50. Gupta S.K., Eustace J.A., Winston J.A., Boydstun I.I., Ahuja T.S., Rodríguez R.A., et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 40 (2005) 1559-1585
51. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999) 461-470
52. Levey A.S., Coresh J., Balk E., Kausz A.T., Levin A., Steffes M.W., et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
53. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
54. Gatanaga H., Tachikawa N., Kikuchi Y., Teruya K., Genka I., Honda M., et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 22 (2006) 744-748
55. National Kidney Foundation. NKF-KDOQI Guidelines [consultado 15/1/2009]. Disponible en: http://www.kidney.org/professionals/kdoqi/guidelines.cfm
56. Amanzadeh J., and Reilly Jr. R.F. Hypophosphatemia: An evidence-based approach to its clinical consequences and management. Nat Clin Pract Nephrol 2 (2006) 136-148
57. Day S.L., Leake Date H.A., Bannister A., Hankins M., and Fisher M. Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J Acquir Immune Defic Syndr 38 (2005) 301-304
58. Kopp J.B., Miller K.D., Mican J.A., Feuerstein I.M., Vaughan E., Baker C., et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 127 (1997) 119-125
59. Karras A., Lafaurie M., Furco A., Bourgarit A., Droz D., Sereni D., et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 36 (2003) 1070-1073
60. Peyriere H., Reynes J., Rouanet I., Daniel N., De Boever C.M., Mauboussin J.M., et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35 (2004) 269-273
61. Malik A., Abraham P., and Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment--case report and review of literature. J Infect 51 (2005) E61-E65
62. Krishnan M., Nair R., Haas M., and Atta M.G. Acute renal failure in an HIV-positive 50-year-old man. Am J Kidney Dis 36 (2000) 1075-1078
63. Jaradat M., Phillips C., Yum M.N., Cushing H., and Moe S. Acute tubulointerstitial nephritis attributable to indinavir therapy. Am J Kidney Dis 35 (2000) E16
64. Brewster U.C., and Perazella M.A. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis 44 (2004) e81-e84
65. Lalezari J.P., Henry K., O'Hearn M., Montaner J.S., Piliero P.J., Trottier B., et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348 (2003) 2175-2185
66. Izzedine H., Launay-Vacher V., and Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 19 (2005) 844-845
67. Morris A.A., Baudouin S.V., and Snow M.H. Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors. AIDS 15 (2001) 140-141
68. Izzedine H., Hulot J.S., Vittecoq D., Gallant J.E., Staszewski S., Launay-Vacher V., et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20 (2005) 743-746
69. Gallant J.E., DeJesus E., Arribas J.R., Pozniak A.L., Gazzard B., Campo R.E., et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006) 251-260
70. Arribas J.R., Pozniak A.L., Gallant J.E., DeJesus E., Gazzard B., Campo R.E., et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47 (2008) 74-78
71. Gallant J.E., Parish M.A., Keruly J.C., and Moore R.D. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 40 (2005) 1194-1198
72. Fux C.A., Simcock M., Wolbers M., Bucher H.C., Hirschel B., Opravil M., et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12 (2007) 1165-1173
73. Mauss S., Berger F., and Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 19 (2005) 93-95
74. El Sahly H.M., Teeter L., Zerai T., Andrade R.A., Munoz C., Nnabuife C., et al. Serum creatinine changes in HIV-seropositive patients receiving tenofovir. AIDS 20 (2006) 786-787
75. Padilla S., Gutiérrez F., Masia M., Canovas V., and Orozco C. Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS 19 (2005) 421-424
76. Jones R., Stebbing J., Nelson M., Moyle G., Bower M., Mandalia S., et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study. J Acquir Immune Defic Syndr 37 (2004) 1489-1495
77. Scott J.D., Wolfe P.R., Bolan R.K., and Guyer B. Serious renal impairment occurs rarely with use of tenofovir DF. HIV Clin Trials 7 (2006) 55-58
78. Nelson M.R., Katlama C., Montaner J.S., Cooper D.A., Gazzard B., Clotet B., et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21 (2007) 1273-1281
79. Kiser J.J., Aquilante C.L., Anderson P.L., King T.M., Carten M.L., and Fletcher C.V. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr 47 (2008) 298-303
80. Izzedine H., Hulot J.S., Villard E., Goyenvalle C., Domínguez S., Ghosn J., et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 194 (2006) 1481-1491
81. Goicoechea M., Liu S., Best B., Sun S., Jain S., Kemper C., et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197 (2008) 102-108
82. Wai H, Katsivas T, Ballard C, Barber E, Mathews C. Risk Factors for Tenofovir-associated Nephrotoxicity Identified in an HIV Clinic Cohort. [Abstract 833]. 14th Conference on Retroviruses and Opportunistic Infections. Boston, February 3-6, 2008.
83. Crane H.M., Kestenbaum B., Harrington R.D., and Kitahata M.M. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 21 (2007) 1431-1439
84. Masia M., Gutiérrez F., Padilla S., Ramos J.M., and Pascual J. Severe toxicity associated with the combination of tenofovir and didanosine: Case report and review. Int J STD AIDS 16 (2005) 646-648
85. Castellano C, Williams W, Kepler TB, Kim S, Szszech L, Hicks C. Clinical predictors of tenofovir-associated nephrotoxicity in HIV-1-infected patients. [Asbtract WEAB0104]. XVII International AIDS Conference. Mexico City, August 3-8, 2008.
86. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265-72. Epub 2007 Jun 27.
87. Gupta S.K. Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system. AIDS Patient Care STDS 22 (2008) 99-103
88. Lundgren JD, Battegay M, Behrens G, De Wit S, Guaraldi G, Katlama C, et al; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9:72-81.
89. Viread. Ficha técnica del producto [consultado 5/10/2009]. Disponible en http://www.emea.europa.eu/humandocs/PDFs/EPAR/viread/H-419-PI-es.pdf
90. Post F.A., and Holt S.G. Recent developments in HIV and the kidney. Curr Opin Infect Dis 22 (2009) 43-48
91. Ahuja T.S., Collinge N., Grady J., and Khan S.I. Dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy?. Am J Kidney Dis 41 (2003) 1060-1064
92. Fabian J., Katz I., Gerntholtz T., and Goetsch S. Naicker SChronic kidney disease in human immunodeficiency virus infection. Panminerva Med 49 (2007) 51-66
93. Khanna R., Tachopoulou O.A., Fein P.A., Chattopadhyay J., and Avram M.M. Survival experience of peritoneal dialysis patients with human immunodeficiency virus: A 17-year retrospective study. Adv Perit Dial 21 (2005) 159-163
94. Rivera Gorrin M., Merino Rivas J.L., Alarcón Garcelán M.C., Galeano Álvarez C., Manuel O., Teruel Briones J.L., et al. [Outcome of HIV-infected patients of peritoneal dialysis: Experience in a center and literature review]. Nefrología 28 (2008) 479-482
95. Mesquita M., Guillaume M.P., and Dratwa M. First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis. Clin Drug Investig 27 (2007) 727-729
96. Tourret J., Tostivint I., Du Montcel S.T., Bragg-Gresham J., Karie S., Vigneau C., et al. Outcome and prognosis factors in HIV-infected hemodialysis patients. Clin J Am Soc Nephrol 1 (2006) 1241-1247
97. Curi M.A., Pappas P.J., Silva Jr. M.B., Patel S., Padberg Jr. F.T., Jamil Z., et al. Hemodialysis access: Influence of the human immunodeficiency virus on patency and infection rates. J Vasc Surg 29 (1999) 608-616
98. Mitchell D., Krishnasami Z., Young C.J., and Allon M. Arteriovenous access outcomes in haemodialysis patients with HIV infection. Nephrol Dial Transplant 22 (2007) 465-470
99. Mitchell D., Krishnasami Z., and Allon M. Catheter-related bacteraemia in haemodialysis patients with HIV infection. Nephrol Dial Transplant 21 (2006) 3185-3188
100. Barril G, González Parra E, Alcázar R, Arenas D, Campistol JM, Caramelo C, et al. [Guidelines on hemodialysis-associated viral infections]. Nefrologia. 2004;24 Suppl 2:43-66.
101. Barril G., Trullás J.C., González-Parra E., Moreno A., Bergada E., Jofre R., et al. Prevalence of HIV-1-infection in dialysis units in Spain and potential candidates for renal transplantation: results of a Spanish survey. Enferm Infecc Microbiol Clin 23 (2005) 335-339
102. Miró J.M., Torre-Cisnero J., Moreno A., Tuset M., Quereda C., Laguno M., et al. GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005). Enferm Infecc Microbiol Clin 23 (2005) 353-362
103. Trullas J.C., Cofan F., Cocchi S., Cervera C., Linares L., Agüero F., et al. Effect of thymoglobulin induction on HIV-infected renal transplant recipients: Differences between HIV-positive and HIV-negative patients. AIDS Res Hum Retroviruses 23 (2007) 1161-1165
104. Trullás J.C., Miró J.M., Barril G., Ros S., Burgos F.J., Moreno A., et al. Renal transplantation in patients with HIV infection. Enferm Infecc Microbiol Clin 23 (2005) 363-374
105. Mazuecos A., Pascual J., Gómez E., Sola E., Cofán F., López F., et al. Renal transplantation in HIV-infected patients in Spain. Nefrología 26 (2006) 113-120